VIVUS, Inc. news

   Watch this stock
Showing stories 1 - 5 of about 5   

Articles published

VVUS 1.27 +0.04 (3.25%)
price chart
FDA Approves First New Weight-Loss Drug In More Than A Decade
The FDA had rejected Qnexa in 2010 because of concerns about heart problems and birth defects. But Vivus, maker of Qnexa, submitted additional data aimed at alleviating those concerns.
Prescription Drug to Aid Weight Loss Wins FDA Backing  New York Times
Diet Drug Wins FDA's Approval  Wall Street Journal
Weight-loss pill Belviq gets the OK from the FDA
Vivus Inc.'s Qnexa is thought to be the most promising of the drugs, achieving the most weight loss. But the FDA has delayed a decision on that pill until July.
Chesapeake Energy Stock
26% on Vivus Inc. September 24 calls. 84% on Arena Pharmaceuticals July 8 calls. 45% on Arena Pharmaceuticals July 8 puts. And 30% on Facebook 30 calls.
Top 10 Healthcare ETFs
The healthcare sector as a more defensive sector overall remains a positive holding in 2012 despite volatility in overall markets.
Investing in Obesity Killers: Orlistat and the Competition
Believe it or not, the weight loss sector contains more companies than Vivus (NASDAQ: VVUS) and Arena Pharmaceuticals (NASDAQ: ARNA).